Glenmark Pharmaceuticals Limited EBIT

Glenmark Pharmaceuticals Limited (GLENMARK.BO) currently reports a EBIT of $27B as of June 2026. That compares with $15B in the prior-year period — up 80.1% year over year. That is above the sector sector average of $-25M. Use the charts on this page to explore Glenmark Pharmaceuticals Limited's EBIT history and peer comparisons.

Glenmark Pharmaceuticals Limited's EBIT increased from $15B to $27B — a 80.1% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Glenmark Pharmaceuticals Limited's EBIT of $27B is higher than the its sector sector average of $-25M. That is roughly 108118.3% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Glenmark Pharmaceuticals Limited reported $27B in EBIT as of June 2026. That compares with $15B in the prior-year period — up 80.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $27B, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $-25M. From there, open related valuation or income-statement pages for Glenmark Pharmaceuticals Limited, and consider following GLENMARK.BO for alerts when major investors trade the stock.